Your browser is no longer supported. Please, upgrade your browser.
Settings
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.94 Insider Own22.90% Shs Outstand30.29M Perf Week-8.61%
Market Cap2.64B Forward P/E- EPS next Y-7.13 Insider Trans-18.72% Shs Float22.50M Perf Month-24.44%
Income-309.20M PEG- EPS next Q-2.52 Inst Own72.70% Short Float19.57% Perf Quarter-23.31%
Sales179.80M P/S14.66 EPS this Y24.50% Inst Trans1.37% Short Ratio3.84 Perf Half Y-16.92%
Book/sh0.64 P/B135.95 EPS next Y24.90% ROA-59.90% Target Price160.60 Perf Year25.68%
Cash/sh14.40 P/C6.04 EPS next 5Y-8.89% ROE-591.20% 52W Range64.50 - 133.74 Perf YTD-13.67%
Dividend- P/FCF- EPS past 5Y-23.60% ROI-73.10% 52W High-33.24% Beta1.58
Dividend %- Quick Ratio4.20 Sales past 5Y156.40% Gross Margin98.60% 52W Low38.42% ATR5.19
Employees330 Current Ratio4.20 Sales Q/Q41.40% Oper. Margin- RSI (14)34.15 Volatility4.80% 4.73%
OptionableYes Debt/Eq19.44 EPS Q/Q33.00% Profit Margin- Rel Volume0.93 Prev Close87.01
ShortableYes LT Debt/Eq19.44 EarningsMay 30 BMO Payout- Avg Volume1.15M Price89.28
Recom2.00 SMA20-16.00% SMA50-16.12% SMA200-16.03% Volume376,695 Change2.61%
Mar-01-19Upgrade RBC Capital Mkts Sector Perform → Outperform $130
Feb-22-19Downgrade SVB Leerink Mkt Perform → Underperform $70
Feb-15-19Reiterated BofA/Merrill Underperform $68 → $79
Feb-04-19Upgrade Raymond James Outperform → Strong Buy $184
Jan-31-19Initiated Credit Suisse Outperform $167
Jan-30-19Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jan-23-19Initiated UBS Buy $130
Jan-14-19Upgrade Laidlaw Hold → Buy $130
Dec-12-18Initiated B. Riley FBR Buy $155
Nov-19-18Upgrade Oppenheimer Perform → Outperform
Oct-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-01-18Resumed Cantor Fitzgerald Overweight $170
Sep-12-18Initiated ROTH Capital Buy $192
Aug-15-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-18Upgrade Goldman Sell → Buy
Aug-03-18Downgrade Laidlaw Buy → Hold $90 → $95
Jun-28-18Initiated Raymond James Strong Buy
Feb-07-18Downgrade Goldman Neutral → Sell
Nov-01-17Upgrade Laidlaw Hold → Buy $90
Nov-01-17Upgrade Cantor Fitzgerald Underweight → Neutral $69
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
Apr-16-19 07:43PM  3 Top Healthcare Stocks to Buy in April Motley Fool
Apr-15-19 04:26PM  Gilead to Collaborate with Novo Nordisk for NASH Treatment Zacks
Apr-11-19 09:16PM  Why Intercept's Success Was a Big Disappointment Motley Fool -13.20%
04:39PM  Why Intercept Pharmaceuticals, Weight Watchers International, and Canopy Growth Slumped Today Motley Fool
11:26AM  Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event? Benzinga
10:03AM  Intercept Reports Additional Positive Data From NASH Study Zacks
07:48AM  The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug Benzinga
02:00AM  Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH GlobeNewswire
Apr-07-19 05:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Apr-04-19 07:00AM  Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress 2019 GlobeNewswire
Apr-02-19 07:44PM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
Apr-01-19 04:57PM  Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics Zacks
Mar-31-19 09:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Mar-30-19 11:31AM  2 Biotechs With Big Dates in April Motley Fool
10:15AM  How Many Insiders Sold Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares? Simply Wall St.
09:30AM  Why Is Intercept (ICPT) Up 12.2% Since Last Earnings Report? Zacks
Mar-22-19 05:43PM  Conatus (CNAT) Declines on Failure of NASH Fibrosis Study Zacks
10:49AM  Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo Benzinga
Mar-06-19 10:44PM  Edited Transcript of ICPT earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
09:35AM  Why Intercept Pharmaceuticals Stock Hit the Skids in February Motley Fool
Mar-05-19 05:00PM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
08:30AM  New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-02-19 07:48AM  Intercept Pharmaceuticals Inc (ICPT) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-01-19 11:49AM  Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus Zacks +6.97%
Feb-28-19 08:57PM  Intercept Pharmaceuticals (ICPT) Q4 2018 Earnings Conference Call Transcript Motley Fool +7.52%
11:40AM  Why Intercept Pharmaceuticals Stock Is Jumping Today Motley Fool
07:15AM  Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update GlobeNewswire
Feb-27-19 03:00PM  3 Top Mid-Cap Stocks to Buy Right Now Motley Fool
Feb-22-19 09:18PM  3 Top U.S. Stocks to Watch in February Motley Fool
Feb-21-19 10:31AM  Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -7.27%
10:26AM  $35 Billion Market! Positive Clinical Trial! Yet Shares Are Down? Motley Fool
09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 10:18PM  Intercept Pharmaceuticals Investors Strap In for a Wild Ride Motley Fool -15.77%
04:54PM  Here's Why Intercept Pharmaceuticals Changed Course Today Motley Fool
04:30PM  Intercept to Announce Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019 GlobeNewswire
10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
08:52AM  Intercept Pharmaceuticals (ICPT) Surges: Stock Moves 6.1% Higher Zacks
08:11AM  Intercept Reports Positive Top-Line Data for NASH, Shares Up Zacks
Feb-19-19 04:30PM  After Gilead Failed, Intercept Stock Rises On NASH Treatment Study Investor's Business Daily +6.09%
04:24PM  Why Intercept Pharmaceuticals, PG&E, and Superior Energy Services Jumped Today Motley Fool
03:38PM  5 Top Stock Trades for Wednesday: Apple, Facebook and Gold InvestorPlace
01:10PM  Intercept Pharmaceuticals News: ICPT Stock Soars on Positive Trial Results InvestorPlace
12:46PM  Shares of Intercept Pharmaceuticals Rise Sharply on Drug Trial Results TheStreet.com
11:42AM  Why Intercept Pharmaceuticals Stock Is Soaring Today Motley Fool
11:40AM  Positive Trial Results for Intercept, Shares a Bargain Morningstar
10:58AM  Intercept Comes in First With Liver Drug, But Race Isnt Over Bloomberg
10:36AM  Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial Benzinga
09:40AM  Intercept Pharmaceuticals up 14% after positive NASH trial results MarketWatch
09:04AM  US STOCKS-Wall St set to open lower as U.S.-China trade talks resume Reuters
07:00AM  Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH GlobeNewswire
Feb-17-19 02:03PM  Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals Motley Fool
Feb-13-19 04:22PM  Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure Benzinga
Feb-12-19 04:20PM  Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails Zacks -5.36%
Feb-10-19 09:19AM  Is Intercept Pharmaceuticals a Buy? Motley Fool
Feb-06-19 10:30AM  Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-31-19 07:55AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Moderna ACCESSWIRE
Jan-30-19 04:00PM  JMP Upgrades Intercept Pharma Ahead Of NASH Trial Data Benzinga
Jan-29-19 03:45PM  The Biggest Biotech Binary Event in 2019 Is Just Around the Corner Motley Fool
Jan-11-19 06:11PM  NASH Space in Focus in 2019 as Firms Look to Diversify Zacks
08:56AM  Are Options Traders Betting on a Big Move in Intercept Pharmaceuticals (ICPT) Stock? Zacks
Jan-07-19 09:09AM  Gilead (GILD) Collaborates With Yuhan for NASH Candidates Zacks +7.26%
07:00AM  Intercept Announces NASH and PBC Program Updates GlobeNewswire
Jan-02-19 04:05PM  Intercept to Present at Upcoming Investor Conference GlobeNewswire
Dec-30-18 08:39AM  The $35 billion race to cure a liver disease that affects 30 million Americans CNBC
Dec-28-18 04:52PM  Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018 Zacks
08:21AM  My Top Portfolio Holdings for 2019 Motley Fool
Dec-26-18 08:18AM  Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics Motley Fool +9.76%
Dec-24-18 10:08AM  Health care going negative after starting quarter strong CNBC Videos
Dec-21-18 12:22PM  Is Intercept Pharmaceuticals, Inc.s (NASDAQ:ICPT) CEO Pay Justified? Simply Wall St. -7.02%
Dec-17-18 12:19AM  Hedge Funds Are Betting On Intercept Pharmaceuticals Inc (ICPT) Insider Monkey
Dec-13-18 12:02PM  The 10 Best Stocks to Buy to Finish Out 2018 InvestorPlace
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Dec-09-18 11:33AM  Better Buy: Intercept Pharmaceuticals vs. Genfit Motley Fool
Dec-03-18 08:56AM  Are Options Traders Betting on a Big Move in Intercept Pharmaceuticals (ICPT) Stock? Zacks
07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Caesars Entertainment, Intercept Pharmaceuticals, Exxon Mobil, Teligent, Amerco, and Mettler-Toledo International New Research Emphasizes Economic Growth GlobeNewswire
Nov-30-18 09:31AM  Why Is Intercept (ICPT) Up 4% Since Last Earnings Report? Zacks
Nov-29-18 07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Amicus Therapeutics ACCESSWIRE
Nov-16-18 07:15PM  Intercept Pharmaceuticals Inc (ICPT) President & CEO Mark Pruzanski Sold $5.1 million of Shares GuruFocus.com
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-13-18 08:00AM  Why Viking Therapeutics Stock Is Bolting Higher Today Motley Fool
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace -7.39%
09:24AM  Why Intercept Pharmaceuticals, Inc. Stock Broke Down in October Motley Fool
Nov-08-18 09:35PM  Edited Transcript of ICPT earnings conference call or presentation 31-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
07:05AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics ACCESSWIRE
Nov-05-18 07:00AM  Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018 GlobeNewswire
Nov-01-18 07:34AM  Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3 Zacks +10.26%
Oct-31-18 08:55AM  Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates Zacks +10.09%
07:50AM  Intercept: 3Q Earnings Snapshot Associated Press
07:27AM  Intercept Pharma stock rises 3.2% on narrower-than-expected Q3 loss MarketWatch
07:05AM  Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-27-18 07:18AM  Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals Motley Fool
07:00AM  Where Will Gilead Sciences, Inc. Be in 5 Years? Motley Fool
Oct-25-18 09:21AM  3 Top Mid-Cap Stocks to Buy Immediately Motley Fool
Oct-24-18 04:05PM  Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018 GlobeNewswire -7.43%
07:50AM  Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and ViewRay Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-17-18 02:27PM  5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage InvestorPlace
Oct-16-18 03:01PM  Can This Tiny Biotech Revolutionize a $35 Billion Market? Motley Fool +6.00%
10:00AM  Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock Motley Fool
Oct-11-18 09:00AM  Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September Motley Fool
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cawkwell GailSVP, Med Affairs, Safety & PVApr 18Option Exercise54.631,75095,60319,599Apr 22 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Option Exercise31.902,00063,80041,499Apr 16 07:01 PM
Shapiro DavidChief Medical OfficerApr 15Sale95.002,000190,00039,499Apr 16 07:01 PM
Bright LisaPresident, InternationalApr 03Sale115.0159468,31620,982Apr 03 07:01 PM
Shapiro DavidChief Medical OfficerApr 03Sale115.0156264,63639,499Apr 03 07:00 PM
Fundaro PaoloDirectorMar 29Sale107.452,171233,27211,114Mar 29 07:00 PM
Shapiro DavidChief Medical OfficerMar 01Option Exercise31.902,00063,80042,543Mar 01 07:00 PM
Weyer ChristianEVP, Research & DevelopmentMar 01Sale103.1633334,35219,107Mar 01 07:00 PM
Shapiro DavidChief Medical OfficerMar 01Sale103.162,000206,32040,543Mar 01 07:00 PM
AKKARAJU SRINIVASDirectorFeb 19Sale128.7823,4383,018,346210,937Feb 21 08:33 PM
Shapiro DavidChief Medical OfficerFeb 15Option Exercise31.902,00063,80042,543Feb 20 09:01 PM
Shapiro DavidChief Medical OfficerFeb 15Sale111.512,000223,02040,543Feb 20 09:01 PM
Bright LisaPresident, InternationalJan 07Sale104.931,313137,77318,807Jan 09 08:00 PM
Shapiro DavidChief Medical OfficerJan 04Sale97.4847446,20637,243Jan 04 07:01 PM
Shapiro DavidChief Medical OfficerJan 03Sale97.4569968,11837,717Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerJan 02Option Exercise31.902,00063,80040,416Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerJan 02Sale98.282,000196,56038,416Jan 03 07:04 PM
Shapiro DavidChief Medical OfficerDec 17Option Exercise31.902,00063,80041,152Dec 19 07:00 PM
Shapiro DavidChief Medical OfficerDec 17Sale106.622,000213,24039,152Dec 19 07:00 PM
Bright LisaPresident, InternationalDec 04Sale111.0030033,30021,288Dec 06 07:00 PM
Bright LisaPresident, InternationalDec 03Sale111.454,700523,82121,588Dec 06 07:00 PM
Micheli Francesco10% OwnerNov 29Sale105.07750,00078,802,5006,095,578Dec 03 04:34 PM
Genextra S.p.A.10% OwnerNov 29Sale105.07750,00078,802,5006,095,578Dec 03 04:31 PM
Weyer ChristianEVP, Research & DevelopmentNov 29Sale113.781,343152,80715,819Nov 29 07:00 PM
Pruzanski MarkPresident & CEONov 16Option Exercise8.6727,606239,253594,411Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 16Sale101.5427,6062,803,129566,805Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 15Option Exercise8.6722,394194,082589,199Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 15Sale100.5022,3942,250,585566,805Nov 16 07:00 PM
Shapiro DavidChief Medical OfficerNov 01Option Exercise21.502,00043,00041,152Nov 02 07:01 PM
Shapiro DavidChief Medical OfficerNov 01Sale96.322,000192,64039,152Nov 02 07:01 PM
Shapiro DavidChief Medical OfficerOct 15Option Exercise21.503,42573,63842,577Oct 16 07:00 PM
Shapiro DavidChief Medical OfficerOct 15Sale102.953,425352,60439,152Oct 16 07:00 PM
Shapiro DavidChief Medical OfficerOct 05Sale110.6575983,98339,152Oct 05 07:01 PM
Shapiro DavidChief Medical OfficerSep 05Sale111.434,917547,89142,196Sep 07 06:00 PM